Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRX

Hisse Senetlerindeki Sıralama #4164
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Hisse Fiyatı
$31.49
Son senkronizasyon: 2026-07-21
Piyasa Değeri
$3.85B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
49.88%
Ülke
US
Ticaret Catalyst Pharmaceuticals, Inc. (CPRX)

Kategori

Healthcare
Catalyst Pharmaceuticals, Inc. (CPRX) için tedavüldeki hisse sayısı
March 2026 itibarıyla tedavüldeki hisse sayısı: 122.25M
Catalyst Pharmaceuticals, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 122.25M'dir. December 2023 sonunda şirketin 106.28M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Catalyst Pharmaceuticals, Inc. (CPRX) için 2002 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
Yıl Tedavüldeki Hisse Sayısı Değiştir
2026 (TTM) 122.25M 3.20%
2024 118.46M 11.46%
2023 106.28M 2.81%
2022 103.37M 0.00%
2021 103.38M -0.13%
2020 103.51M 0.55%
2019 102.94M 0.30%
2018 102.63M 19.62%
2017 85.80M 3.53%
2016 82.88M 2.49%
2015 80.86M 26.06%
2014 64.14M 41.12%
2013 45.45M 51.34%
2012 30.03M 38.22%
2011 21.73M 16.94%
2010 18.58M 23.32%
2009 15.07M 15.78%
2008 13.01M 3.89%
2007 12.53M 62.93%
2006 7.69M 23.90%
2005 6.20M 112.61%
2004 2.92M 0.00%
2003 2.92M 23.73%
2002 2.36M 0.00%
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
Şirket Tedavüldeki Hisse Sayısı Fark Ülke
253.90M 107.68%
US
396.00M 223.92%
US
478.91M 291.73%
AU
- -
CH
62.19M -49.13%
NL